Prometheus Biosciences raises deal size by 33% ahead of $167 million IPO

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, raised the proposed deal size for its upcoming IPO on Thursday.

The San Diego, CA-based company now plans to raise $167 million by offering 9 million shares at a priceRead More